Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05833542 · ClinicalTrials.gov registry record · NA
Assessing Perceptions and Preferences Around Long-acting Injectables (APPLI)
A NA study, sponsored by City University of New York.
- Completed
- Registry status
- NA
- Development phase
- 243
- Enrollment target
NCT05833542: Completed NA study, sponsored by City University of New York.
NCT05833542 is a NA study that has completed, run by City University of New York. The registered enrollment target is 243 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05833542, a NA study, has completed, sponsored by City University of New York.
- COMPLETED
- Registry status
- NA
- Development phase
- 243 participants
- Enrollment target
Study Summary
The Ryan White HIV/AIDS Program is an essential platform for reducing health disparities among people with HIV and scaling up evidence-based strategies to strengthen the HIV care continuum. The investigators propose an implementation-science study based in New York Ryan White Part A programs, to inform the delivery of long-acting injectable antiretroviral therapy and related supportive services to low-income, largely Black and Latino/a people with HIV who have struggled with daily oral antiretroviral therapy adherence. As a major biomedical advance de-necessitating adherence to daily dosing, long-acting injectable antiretroviral therapy could greatly increase opportunities for health, survival and transmission prevention, particularly in populations confronting complex barriers to viral load suppression. However, optimizing the public health impact of long-acting injectable antiretroviral therapy will require implementation science to assess perceptions and preferences around long-acting injectable versus daily oral regimens, identify support services and delivery mechanisms suited to promoting long-acting injectable uptake and engagement, and address the role of provider beliefs as to which patients should be offered long-acting injectable options. In the absence of this groundwork, long-acting injectable antiretroviral therapy may primarily reach those who are already relatively advantaged, and even exacerbate HIV disparities.
Primary Outcome
The proportion of participants who start long-acting injectable therapy - including any transition from a prior regimen and any transition from a period of non-antiretroviral use or as a first antiretroviral regimen. The denominator includes patients not already on a long-acting injectable regimen at the start of the study period; the numerator includes any of those in the denominator who begin a long-acting injectable antiretroviral regimen during the study period.
Interventions
- BEHAVIORAL Health education materials
- BEHAVIORAL Patient-provider decision tool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2023-05-03 |
| Est. Completion | 2024-09-30 |
| Phase | NA |
What the finished NCT05833542 record still lists
NCT05833542 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Health education materials is the first listed.
NCT05833542 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05833542 about?
NCT05833542 is a clinical study titled "Assessing Perceptions and Preferences Around Long-acting Injectables (APPLI)". The Ryan White HIV/AIDS Program is an essential platform for reducing health disparities among people with HIV and scaling up evidence-based strategies to strengthen the HIV care continuum. The investigators propose an implementation-science study based in New York Ryan White Part A programs, to inf...
What is the current status of trial NCT05833542?
This trial is currently completed. It is a NA study. The enrollment target is 243 participants. The study started on 2023-05-03. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT05833542?
The interventions under investigation include: Health education materials (BEHAVIORAL), Patient-provider decision tool (BEHAVIORAL).
Who is sponsoring clinical trial NCT05833542?
This trial is sponsored by City University of New York, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05833542's enrollment target sits among peer trials
243 438th of 2000 higher than 1,562 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT06907615 · 243 participants · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI